Immune checkpoint inhibitors targeting programmed cell death protein 1/programmed cell death-ligand 1 have become a new standard for treatment of advanced small cell lung cancers.[13] PD-L1 expression is very low in mucinous adenocarcinomas. The gene discussed is CD274; the disease is mucinous adenocarcinoma.